PTC THERAPEUTICS INC (PTCT)
US69366J2006 - Common Stock
Overall PTCT gets a fundamental rating of 2 out of 10. We evaluated PTCT against 574 industry peers in the Biotechnology industry. Both the profitability and financial health of PTCT have multiple concerns. PTCT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PTCT had negative earnings in the past year.
PTCT had a negative operating cash flow in the past year.
PTCT had negative earnings in each of the past 5 years.
PTCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PTCT has a Return On Assets of -25.02%. This is in the better half of the industry: PTCT outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.02% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-30.95%
ROA(5y)-25.64%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 92.35%, PTCT belongs to the best of the industry, outperforming 94.01% of the companies in the same industry.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
PTCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-0.47%
2. Health
2.1 Basic Checks
PTCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
PTCT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PTCT has more shares outstanding
PTCT has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.44, we must say that PTCT is in the distress zone and has some risk of bankruptcy.
PTCT has a Altman-Z score of -1.44. This is comparable to the rest of the industry: PTCT outperforms 54.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.44 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
PTCT has a Current Ratio of 2.23. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT has a worse Current ratio (2.23) than 75.70% of its industry peers.
PTCT has a Quick Ratio of 2.17. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT has a worse Quick ratio (2.17) than 74.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.23 | ||
| Quick Ratio | 2.17 |
3. Growth
3.1 Past
PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.84%, which is quite impressive.
Looking at the last year, PTCT shows a quite strong growth in Revenue. The Revenue has grown by 9.99% in the last year.
PTCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.79% yearly.
EPS 1Y (TTM)43.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.26%
Revenue 1Y (TTM)9.99%
Revenue growth 3Y35.04%
Revenue growth 5Y28.79%
Sales Q2Q%-12.68%
3.2 Future
The Earnings Per Share is expected to grow by 18.55% on average over the next years. This is quite good.
Based on estimates for the next years, PTCT will show a small growth in Revenue. The Revenue will grow by 6.40% on average per year.
EPS Next Y21.47%
EPS Next 2Y20.03%
EPS Next 3Y20.86%
EPS Next 5Y18.55%
Revenue Next Year-21.9%
Revenue Next 2Y-14.07%
Revenue Next 3Y-4.09%
Revenue Next 5Y6.4%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PTCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PTCT indicates a rather cheap valuation: PTCT is cheaper than 93.13% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 369.18 |
4.3 Compensation for Growth
A more expensive valuation may be justified as PTCT's earnings are expected to grow with 20.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.03%
EPS Next 3Y20.86%
5. Dividend
5.1 Amount
No dividends for PTCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PTC THERAPEUTICS INC
NASDAQ:PTCT (9/6/2024, 8:00:00 PM)
After market: 31.54 0 (0%)31.54
-0.06 (-0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.42B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.02% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.35% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.23 | ||
| Quick Ratio | 2.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)43.84%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y21.47%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)9.99%
Revenue growth 3Y35.04%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y